JPRN-jRCTc030210068招募中1 期
WT1 peptide-pulsed dendritic cell therapy for wet age-related macular degeneration
Gunji Hisato0 个研究点目标入组 10 人开始时间: 2021年5月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Clinically diagnosed with wet age-related macular degeneration
- •2) The name of the disease in 1) has been announced.
- •3) HLA type is HLA-A (A * 2402, A * 0201, A * 0206), HLA-DR (DRB1 * 0101, DRB1 * 0405, DRB1 * 0802, DRB1 * 0803, DRB1 * 0901, DRB1 * 1201, DRB1 * 1403, DRB1 * 1501, DRB1 * 1502, DRB5 * 0102), HLA-DP (DPB1 * 0201, DPB1 * 0202, DPB1 * 0402, DPB1 * 0501, DPB1 * 0901), HLA-DQ (DQB1 * 0301, One of DQB1 * 0302, DQB1 * 0401, DQB1 * 0501, DQB1 * 0601, DQB1 * 0602.
- •4) Outpatient visits are possible according to the research implementation schedule.
- •5) Patient without treatment for cancer.
- •6) Over 50 years of age
- •7) Patients who retain the functions of major organs (confirmed by pre-registration examination).
- •8) Written consent from the patient has been obtained for participation in this study.
- •9) Meet the apheresis eligibility criteria for dendritic cell production
排除标准
- •1) Have an uncontrolled infectious disease
- •2) Serious complications: malignant hypertension, severe congestive heart failure, severe coronary failure, unstable edema or myocardial infarction within 12 months, severe arrhythmia requiring medication and more than 2nd degree Patients with conduction abnormalities such as AV block, liver cirrhosis, uncontrolled diabetes, pulmonary fibrosis, interstitial pneumonia, marked peripheral edema, etc. active infections, active hepatitis B
- •3) Patients who are considered unsuitable for participation in this clinical trial due to complications or whose safety may be compromised due to serious medical events.
- •4) Cases in which antitumor treatment such as chemotherapy / radiochemotherapy was performed within 1 year
- •5) Have serious complications
- •6) Patients with myelodysplastic syndrome, myelodysplastic / myeloproliferative disorders and chronic myelogenous leukemia
- •7) History of severe drug hypersensitivity (excluding iodine contrast media)
- •8) Patients with severe mental illness
- •9) Patients with autoimmune disease
- •10) Patients with a history of allergies to OK-432 and penicillin G
- •11) Pregnant or lactating women
- •12) Pregnant women who are not willing to contracept
研究者
相似试验
已完成
不适用
Immunotherapy using WT1 peptide against recurrent glioblastoma multiforme: A phase I/II study.glioblastoma multiformeJPRN-UMIN000002024Cancer Vaccination Therapy Research Network, Department of Immunology, Kochi Medical School30
已完成
1 期
Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against malignant bone and soft tissue tumors: A phase I/II studyMalignant bone and soft tissue tumorsJPRN-UMIN000010257Department of Orthopaedic Surgery, Kochi Medical School20
已完成
不适用
Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against Head and Neck Tumor: A phase I/II studyHead and Neck TumorJPRN-UMIN000001906Anti-tumor Immunotherapy Research Network, Department of Immunology, Kochi Medical School65
招募中
1 期
Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against recurrent prostate cancer: A phase I/II studyProstate cancerJPRN-UMIN000001821Department of Immunology, Kochi University School of Medicine60
招募中
1 期
Immunotherapy using WT1 peptide with surgical treatment, irradiation therapy, and Temozolomide administration against glioblastoma multiforme: A phase I/II study.glioblastoma multiformeJPRN-UMIN000002419Cancer Vaccination Therapy Research Network, Department of Immunology, Kochi Medical School45